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WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to review guidelines in current use and under
development to determine similarities, emerging trends
and the implications for the use and development of
guidelines in the future.
PARTICIPANTS WHO WOULD BENEFIT: Those who
want to develop an understanding of the guidelines pro-
cess and the means of establishing appropriate study de-
sign criteria to apply in international pharmacoeconomic
studies in order to meet the requirements of as many
guidelines as possible.
Guidelines for the economic evaluation of pharmaceuticals
are being developed around the world by academia, indus-
try, government, payers and external consultants. These
guidelines can be categorized according to their main pur-
pose: methods guidelines; guidelines for formulary submis-
sions; principles of conduct; and substantiation of evidence
for promotional claims. Review of the guidelines reveals a
number of common themes which will allow some com-
parison of studies across countries. Differences outside
these common themes may be attributable to particular
differences in the settings in which individual guidelines
are applicable. However, what is most noticeable is the
trends emerging from what appears to be a flourishing
field of guidelines development. Methodological trends are
evident in study design (with greater acceptance of model-
ling studies), valuation of health outcomes and productiv-
ity changes (indirect costs). In addition, the formal require-
ment for economic evaluation of pharmaceuticals is being
extended into more countries and we can expect to see
pharmacoeconomic guidelines being increasingly used. If
this encourages cost-effective prescribing then the ultimate
impact will be in providing benefit to patients.
WTG2
UPDATE ON THE SCRIPT PROJECT
Westrick E
Rhode Island Quality Partners, Providence, RI, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop is to update participants on the progress of the
SCRIPT project.
PARTICIPANTS WHO WOULD BENEFIT: Stakehold-
ers in medication use quality would benefit by participat-
ing in this workshop.
Background for the SCRIPT project was presented at last
year’s meeting of ISPOR in Philadelphia. Since that time,
there has been significant progress. The SCRIPT project is
the first concerted effort of the Coalition for Quality in
Medication Use. The purpose of the project is to create a
method for consensus-based quality indicator development
and a compendium of core indicators measuring quality in
medication use that will be recommended for implementa-
tion by coalition members. The Coalition for Quality in
Medication Use currently includes about 50 national orga-
nizations. The SCRIPT project is funded by HCFA, and
staffed by JCAHO. Daily management is provided by a
Steering Committee composed of representatives from
AAHP, AHCPR, AHQA, AMA, APhA, HCFA, JCAHO,
NCQA, and two science advisors. The coalition met for the
first time in July 1998. A Call for Measures has gone out
and existing compendia of measures have been collected.
Criteria for evaluating measures are in development and a
technical expert panel is being formed to evaluate the mea-
sures in a cluster of clinical conditions with high disease
burden and significant quality issues in medication use.
Clinical conditions, medication use issues, and some of the
considered measures will be identified at this workshop. Ad-
ditional progress in this area will be shared in the workshop
as well as preliminary plans to test candidate measures.
WTG5
EVALUATION OF FORMULARY DECISIONS: 
PROJECTED IMPACT OF A NEW DRUG 
ROLLOUT WITHIN THE MANAGED CARE 
ARENA
Wright A, Wolff J
Advance Paradigm, Inc., Hunt Valley, MD, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to demonstrate the nature of decision-making
tools employed within the managed care industry to evalu-
ate pharmacy-related issues. This workshop will use an
economic model to demonstrate the type of logic used by
MCOs to project pharmacy costs and to evaluate the im-
pact of formulary changes. Participants will learn how to
utilize pharmacy and medical administrative claims data
to assess the potential increase in pharmacy costs associ-
ated with the introduction of new drugs and/or treatments.
PARTICIPANTS WHO WOULD BENEFIT: Managed
care decision-makers, pharmacy directors, and health econ-
omists who are involved in the evaluation of pharmacy
costs and business issues related to formulary changes.
Rising pharmaceutical expenditures in recent years have
led to increased scrutiny of this benefit among healthcare
insurers in the United States. Managed care organizations
(MCOs) are increasingly questioning available options with
regard to the introduction of new classes of prescription
drugs and other new therapies. Economic models are an im-
portant vehicle that may be utilized by decision-makers to
better understand the financial implications of formulary
changes. We will discuss a model recently developed to
simulate the impact of prescription Cox-2 inhibitor medi-
cations on pharmacy costs of a managed care health plan.
This session will explain the assumptions made, data used,
and processes employed in the development of this eco-
nomic model.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop is to enhance decision-making skills by successfully
applying pharmacoeconomic assessments and the exami-
nation of outcomes research specific to the community
healthcare facility.
PARTICIPANTS WHO WOULD BENEFIT: Health-
care professionals and decision-makers who provide
healthcare from community healthcare facilities.
Community healthcare providers can greatly enhance pa-
tient focused and economic outcomes by performing
their own pharmacoeconomic and outcome studies. Most
community healthcare facilities make decisions based
upon other previous studies that may not reflect their pa-
tient population, community or economic model. This
workshop will enable the participant to identify and ob-
tain vital information that is specific for their facility and
patient population. Incorporating this data into the deci-
sion process will result in developing policy that is more
effective for their facility and community.
WMM5
USING EPIDEMIOLOGIC DATABASES TO 
EXTRAPOLATE LONG-TERM OUTCOMES FROM 
SURROGATE MARKER DATA
Huse DM, Russell, MW
Medical Research International, Burlington, MA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to review the methodological issues involved in
the development of pharmacoeconomic models for pre-
ventive interventions or chronic disease treatments when
the drug’s effects are observed over relatively short time
frames (as in most clinical trials).
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who want to understand how external sources of epi-
demiologic data can be used in conjunction with “surro-
gate marker” data from clinical trials to infer long-term
patient outcomes.
The extended duration of follow-up in large-scale “event”
trials permits researchers to document a drug’s proximal
effects on key biologic measures or “surrogate markers”
and to attribute improvements in long-term patient out-
comes to the drug’s effect on the surrogate marker(s).
While the ability to link short-term effects with long-term
outcomes within a clinical trial is desirable, such studies
are frequently cost-prohibitive. Despite the lack of long-
term follow-up in traditional drug efficacy trials, it is still
possible in many cases to make inferences about a drug’s
long-term effects on patient outcomes. In this workshop,
we will illustrate how statistical models of the relationship
between surrogate markers and outcomes can be devel-
oped using epidemiologic databases, and how these mod-
els can be used in conjunction with surrogate marker and
cost data to estimate long-term clinical and economic con-
sequences of drug therapy. The importance of appropriate
patient identification and selection criteria in epidemio-
logic research will be stressed. A case study will be pre-
sented in which cardiovascular risk equations derived
from the Framingham Heart Study database are used to
estimate reductions in cardiovascular event occurrence
over 1-, 5-, and 10-year time horizons resulting from dec-
rements in diastolic blood pressure (a common surrogate
marker in clinical trials of anti-hypertensive medications).
WMS2
PITFALLS WHEN USING REGRESSION 
EQUATIONS TO ESTIMATE TREATMENT 
IMPACT IN ACTUAL PRACTICE
Caro JJ, Huybrechts KF, Klittich WS
Caro Research, Boston, MA, USA
WORKSHOP OBJECTIVE: To demonstrate how regres-
sion equations should and should not be used when esti-
mating the impact of treatment in actual practice.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers interested in using regression equations in economic
models.
Short of local trials, researchers often resort to using risk
equations, derived from large epidemiological or clinical
studies, to forecast the costs and health consequences of a
new treatment in their target population. In many cases,
the mean risk factor values for the target population are
included directly in the risk equation to calculate the “av-
erage” likelihood of disease for that population. This
common approach may however not be justified, as we
will demonstrate in this workshop, using examples based
on the West of Scotland Coronary Prevention Study. The
results derived in this way do not properly reflect the
clustering of risk factors in the population and are very li-
able to give incorrect outcomes. Instead, epidemiological
studies that contain information on the joint risk factor
distribution in a large number of patients, representative
of the target population, should be identified. These pa-
tient level data should be used to simulate individuals one
at a time and the average risk for the cohort should be
derived as the mean of the individuals’ results. Despite
the increased effort required, this is the only proper tech-
nique to accurately predict the effects of treatment in a
population different from the one used to derive the
equations.
WMS5
ASSESSING THE GENERALIZABILITY OF THE 
RESULTS OF MULTINATIONAL TRIALS FOR 
INDIVIDUAL COUNTRIES PARTICIPATING 
IN THE TRIAL
Glick H, Polsky D
University of Pennsylvania, Philadelphia, PA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to discuss methods for evaluating the gener-
alizability of results from multinational trials. We will
